Navigation Links
Arpida to Restructure and Focus on Key Projects
Date:11/27/2008

REINACH, Switzerland, November 27 /PRNewswire-FirstCall/ -- Arpida announced today that it is refocusing all projects and priorities around the key strategic asset Iclaprim. The company says this is to be seen as a consequence of the negative recommendation of the U.S. Food and Drug Administration (FDA) advisory board on 20 November 2008 regarding the approval of Iclaprim in the U.S.

In the context of the FDA advisory board's recommendation the Arpida board intends to put the company back on a firm footing through cutting costs considerably. To achieve this, the company views the reduction of the workforce by up to 60 employees as inevitable. A consultation process with all employees has been initiated and will lead to decisions by the Board of Directors which will be communicated on 16 December 2008. Board and Management sincerely regret this measure and would like to point out that the company will endeavour to fully assume its social responsibilities. Contact with public authorities on this issue has been established and a social plan will be presented in time.

Arpida will now thoroughly analyse the situation with external experts to determine the future development of Iclaprim. Basis for this analysis will be the full FDA response to the Iclaprim dossier and the publication of the phase II oral step down therapy trial.

"We were very surprised by this very clear negative ruling by the FDA advisory board", CEO Jurgen Raths said. "In particular we are very upset by the steps we are forced to take in regards to our staff. The advisory board's recommendation has come totally unexpected, because we are still convinced that Iclaprim offers a valuable therapeutic asset for the treatment of complicated skin and skin structure infections (cSSSI), especially where MRSA (resistant bacteria called methicillin-resistant staphylococcus aureus) are involved. We will use the FDA's feedback as well as further clinical advice and expertise in our development decisions. We will also continue to cooperate closely with the regulatory agencies in the U.S., Canada and Europe to obtain market authorization for what we think is a valuable asset in the fight against potentially life threatening infections."

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company headquartered in Reinach, Switzerland with operations in Switzerland and the USA. It focuses on the discovery, development and commercialisation of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

    Contact:

    Jurgen Raths, President & CEO
    Phone: +41-61-417-96-66

    Harry Welten, CFO
    Phone: +41-61-417-96-65


'/>"/>
SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arpidas iclaprim MAA Accepted for Review by EMEA
2. Arpida Reports Interim Results for Six Months to 30 June 2008
3. Arpida Announces FDA Acceptance of the Iclaprim New Drug Application
4. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
5. Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company
6. Arpida Announces Conference Call on 17 April
7. Arpida Announces Agenda Items for Shareholders Meeting
8. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
9. Arpida Announces Full Year 2007 Financial Results
10. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
11. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Looking ... team-building and cooking events company, offers one-of-a-kind gifts, ranging from gourmet cooking experiences ... California cuisine, and guests leave inspired with new cooking tips and techniques, thanks ...
(Date:4/26/2017)... ... April 25, 2017 , ... LABS, Inc. (LABS) announced in December ... its extensive test menu: Nucleic Acid Testing (NAT) for ZIKV; and Enzyme Immunoassays (EIAs) ... to offer NAT screening for blood donors under an Investigational New Drug (IND) study ...
(Date:4/26/2017)... ... April 26, 2017 , ... As the call for ... industry stakeholders, the discussion surrounding the topic will continue at WEDI 2017- Driving ... Los Angeles, Calif. Hosted by the Workgroup for Electronic Data Interchange (WEDI), the ...
(Date:4/25/2017)... ... 25, 2017 , ... Franz Inc ., an early ... and market leader for Semantic Graph Database technology, today announced ... most effective system for developing and deploying applications to solve the challenges developers ...
Breaking Biology Technology:
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):